|
Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities
|
10 October 2022 |
|
Lilly will supply an additional 150,000 doses of bebtelovimab to U.S. government
|
14 July 2022 |
|
Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
|
11 February 2022 |
|
Lilly and Lycia Therapeutics enter into strategic collaboration to discover and develop novel lysosomal targeting chimera (LYTAC) degraders
|
25 August 2021 |
|
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
|
03 August 2021 |
|
Lilly and MiNA Therapeutics announce saRNA research collaboration
|
14 May 2021 |
|
Lilly plans donation of COVID-19 therapies to Direct Relief for use in low- and lower-middle-income countries
|
05 May 2021 |
|
EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union
|
09 March 2021 |
|
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial
|
22 January 2021 |
|
Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19
|
07 December 2020 |
|
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives interim authorization from Health Canada as a treatment for COVID-19
|
24 November 2020 |
|
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19
|
13 November 2020 |
|
Data for Lilly's bamlanivimab (LY-CoV555) in COVID-19 outpatients published in New England Journal of Medicine
|
04 November 2020 |
|
Lilly initiates Phase 3 trial of LY-CoV555 for prevention of COVID-19 at long-term care facilities in partnership with the National Institute of Allergy and Infectious Diseases (NIAID)
|
12 August 2020 |
|
Lilly begins world's first study of a potential COVID-19 antibody treatment in humans
|
26 June 2020 |
|
Lilly opens Phase 3 clinical trial in RET-mutant medullary thyroid cancer
|
03 January 2020 |
|
Lilly, Evidation Health and Apple study shows personal digital devices may help in the identification of mild cognitive impairment and mild Alzheimer's disease dementia
|
09 August 2019 |
|
Lilly submits New Drug Application to the FDA for lasmiditan for acute treatment of migraine, receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for prevention of episodic cluster headache
|
15 November 2018 |
|
Lilly to present data for galcanezumab for the prevention of migraine at the American Academy of Neurology (AAN) annual meeting
|
20 April 2017 |
|
Lilly and CoLucid Pharmaceuticals announce agreement for Lilly to acquire CoLucid
|
20 January 2017 |